QuickView for SB-203580 (compound)

1. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
2. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
3. L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
4. L1000 CMAP - Neural progenitor NPC.CAS9 cells treated with small molecule perturbagens
5. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)

1. p38 MAPK inhibitor SB203580 enhances anticancer activity of PARP inhibitor olaparib in a synergistic…
2. SB203580 protects against inflammatory response and lung injury in a mouse model of lipopolysacchari…
3. SB203580, a p38MAPK inhibitor, attenuates olfactory dysfunction by inhibiting OSN apoptosis in AR mi…
4. The p38 MAPK inhibitor, SB203580, inhibits cell invasion by Neospora caninum.
5. Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors.

There were no clinical trials for SB-203580